Naslov
Acute extrapyramidal adverse effects in male schizophrenic patients treated with haloperidol: the association study of polymorphisms in DRD2, SLC6A3, and COMT genes

Autori
Živković, Maja ; Mihaljević-Peleš, Alma ; Božina, Nada ; Šagud, Marina ; Brečić, Petrana ; Bagarić, Dario ; Pejnović, Lana ; Vuksan-Cusa, Bjanka ; Nikolac Perković, Matea ; Muck-Šeler, Dorotea

Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni

Izvornik
Abstract Book: 1st International Conference on Creative Psychopharmacotherapy ICCP 2013 Dubrovnik / - , 2013

Skup
1st International Conference on Creative Psychopharmacotherapy ICCP 2013 Dubrovnik “Psychopharmacology, new insights, philosophies of treatment and stigma and human rights of patients”

Mjesto i datum
Dubrovnik, Hrvatska, 25.09.2013. - 28.09.2013

Vrsta sudjelovanja
Poster

Vrsta recenzije
Međunarodna recenzija

Ključne riječi
schizophrenia; haloperidol; acute extrapyramidal adverse effects; DRD2; SLC6A3; COMT

Sažetak
Objective: Several gene polymorphisms may be important in potential to antipsychotic-induced acute extrapyramidal adverse effects (EPS) in schizophrenia. The goal of this study was to determine association between dopaminergic type 2 receptor (DRD2) dopamine transporter (SLC6A3) and catechol-O-methyltransferase (COMT) gene polymorphisms and acute EPS. Methods: In this study, 240 male schizophrenic patients were recruited and treated with haloperidol (15-mg/day). Acute EPS were observed 2 weeks and assessed with Simpson-Angus Scale (score >3). Three polymorphisms of dopaminergic system, the DRD2 Taq 1A, the SLC6A3 VNTR, and the COMT Val158Met were determined. Result: EPS occurred in 116 (48.3%) of patients. Statistically significant associations were found for SLC6A3 VNTR and COMT Val158Met polymorphisms and EPS susceptibility. Patients with SLC6A3 9/10 genotype had almost two times greater odds to develop EPS compared to those with all other SLC6A3 genotypes (OR=1.9 ; 95% CI=1.13-3.30), and patients with COMT Val/Met genotype had 1.7 odds to develop EPS than those with all other COMT genotypes (OR=1.7 ; 95% CI=1.01-2.88). There was no statistically significant association between any of DRD2, SLC6A3 or COMT genotypes and allele frequencies and the development of any specific EPS. Conclusion: In conclusion, analysis of three genetic variations in the dopaminergic system as predictors of acute neurological adverse events induced haloperidol drug treatment revealed a statistically significant impact SLC6A3 VNTR and COMT Val158Met gene polymorphisms. The precise biological mechanisms underlying these findings are not yet understood. Our results suggest that the dopaminergic gene variations could predict the vulnerability to the development of acute EPS. According to our best knowledge this is the first report which confirmed association between the COMT Val158Met polymorphism and EPS susceptibility.

Izvorni jezik
Engleski

Znanstvena područja
Temeljne medicinske znanosti, Kliničke medicinske znanosti

POVEZANOST RADA